Akdag Serkan, Akyol Aytac, Cakmak Huseyin Altug, Tosu Aydin Rodi, Asker Muntecep, Yaman Mehmet, Babat Naci, Soyoral Yasemin, Cegin Muhammed Bilal, Gur Ali Kemal, Gumrukcuoglu Hasan Ali
Department of Cardiology, Yuzuncu Yil University Medical Faculty, Van, Turkey.
Department of Cardiology, Rize Kackar Government Hospital, Rize, Turkey.
Ther Clin Risk Manag. 2015 Dec 11;11:1829-35. doi: 10.2147/TCRM.S94889. eCollection 2015.
End stage renal disease is related to increased cardiovascular mortality and morbidity. Hypertension is an important risk factor for cardiovascular disorder among hemodialysis (HD) patients. The aim of this study was to investigate the effect of low-sodium dialysate on the systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels detected by ambulatory BP monitoring (ABPM) and interdialytic weight gain (IDWG) in patients undergoing sustained HD treatment.
The study included 46 patients who had creatinine clearance levels less than 10 mL/min/1.73 m(2) and had been on chronic HD treatment for at least 1 year. After the enrollment stage, the patients were allocated low-sodium dialysate or standard sodium dialysate for 6 months via computer-generated randomization.
Twenty-four hour SBP, daytime SBP, nighttime SBP, and nighttime DBP were significantly decreased in the low-sodium dialysate group (P<0.05). No significant reduction was observed in both groups in terms of 24-hour DBP and daytime DBP (P=NS). No difference was found in the standard sodium dialysate group in terms of ABPM. Furthermore, IDWG was found to be significantly decreased in the low-sodium dialysate group after 6 months (P<0.001).
The study revealed that low-sodium dialysate leads to a decrease in ABPM parameters including 24-hour SBP, daytime SBP, nighttime SBP, and nighttime DBP and it also reduces the number of antihypertensive drugs used and IDWG.
终末期肾病与心血管疾病死亡率和发病率的增加相关。高血压是血液透析(HD)患者心血管疾病的重要危险因素。本研究的目的是探讨低钠透析液对接受维持性HD治疗患者动态血压监测(ABPM)检测的收缩压(SBP)和舒张压(DBP)水平以及透析间期体重增加(IDWG)的影响。
该研究纳入了46例肌酐清除率低于10 mL/min/1.73 m²且接受慢性HD治疗至少1年的患者。在入组阶段后,通过计算机生成随机化将患者分配至低钠透析液组或标准钠透析液组,为期6个月。
低钠透析液组的24小时SBP、日间SBP、夜间SBP和夜间DBP均显著降低(P<0.05)。两组在24小时DBP和日间DBP方面均未观察到显著降低(P=无显著性差异)。标准钠透析液组在ABPM方面未发现差异。此外,6个月后发现低钠透析液组的IDWG显著降低(P<0.001)。
该研究表明,低钠透析液可导致ABPM参数降低,包括24小时SBP、日间SBP、夜间SBP和夜间DBP,并且还可减少所用降压药物的数量以及IDWG。